Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ELDER PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ELDER PHARMA DIVIS LABORATORIES ELDER PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -0.2 59.6 - View Chart
P/BV x 0.1 13.7 0.7% View Chart
Dividend Yield % 0.0 0.4 -  

Financials

 ELDER PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    ELDER PHARMA
Jun-14
DIVIS LABORATORIES
Mar-19
ELDER PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3801,639 23.2%   
Low Rs1881,115 16.9%   
Sales per share (Unadj.) Rs491.2186.3 263.6%  
Earnings per share (Unadj.) Rs-3.251.0 -6.2%  
Cash flow per share (Unadj.) Rs14.457.3 25.1%  
Dividends per share (Unadj.) Rs016.00 0.0%  
Dividend yield (eoy) %01.2 0.0%  
Book value per share (Unadj.) Rs376.5261.8 143.8%  
Shares outstanding (eoy) m20.54265.47 7.7%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.67.4 7.8%   
Avg P/E ratio x-89.327.0 -330.3%  
P/CF ratio (eoy) x19.724.0 82.0%  
Price / Book Value ratio x0.85.3 14.3%  
Dividend payout %031.4 0.0%   
Avg Mkt Cap Rs m5,833365,592 1.6%   
No. of employees `000NA11.8 0.0%   
Total wages/salary Rs m2,1795,423 40.2%   
Avg. sales/employee Rs ThNM4,175.1-  
Avg. wages/employee Rs ThNM457.7-  
Avg. net profit/employee Rs ThNM1,141.8-  
INCOME DATA
Net Sales Rs m10,08949,463 20.4%  
Other income Rs m2571,556 16.5%   
Total revenues Rs m10,34651,019 20.3%   
Gross profit Rs m-79218,718 -4.2%  
Depreciation Rs m3611,689 21.4%   
Interest Rs m2,75635 7,875.1%   
Profit before tax Rs m-3,65318,551 -19.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m3,7130-   
Tax Rs m1255,023 2.5%   
Profit after tax Rs m-6513,527 -0.5%  
Gross profit margin %-7.837.8 -20.7%  
Effective tax rate %-3.427.1 -12.7%   
Net profit margin %-0.627.3 -2.4%  
BALANCE SHEET DATA
Current assets Rs m9,24046,501 19.9%   
Current liabilities Rs m9,9988,468 118.1%   
Net working cap to sales %-7.576.9 -9.8%  
Current ratio x0.95.5 16.8%  
Inventory Days Days46131 35.4%  
Debtors Days Days6086 69.8%  
Net fixed assets Rs m10,12425,797 39.2%   
Share capital Rs m206531 38.7%   
"Free" reserves Rs m5,58268,962 8.1%   
Net worth Rs m7,73469,493 11.1%   
Long term debt Rs m4,8890-   
Total assets Rs m22,88280,383 28.5%  
Interest coverage x-0.3531.0 -0.1%   
Debt to equity ratio x0.60-  
Sales to assets ratio x0.40.6 71.7%   
Return on assets %11.816.9 69.7%  
Return on equity %-0.819.5 -4.3%  
Return on capital %22.326.7 83.4%  
Exports to sales %3.00-   
Imports to sales %0.424.6 1.7%   
Exports (fob) Rs m307NA-   
Imports (cif) Rs m4312,187 0.4%   
Fx inflow Rs m30741,238 0.7%   
Fx outflow Rs m12512,405 1.0%   
Net fx Rs m18128,833 0.6%   
CASH FLOW
From Operations Rs m11,7549,543 123.2%  
From Investments Rs m-561-6,854 8.2%  
From Financial Activity Rs m-6,762-2,459 274.9%  
Net Cashflow Rs m4,432230 1,930.2%  

Share Holding

Indian Promoters % 39.6 52.0 76.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 7.5 11.8 63.6%  
FIIs % 16.8 19.0 88.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 36.1 17.2 209.9%  
Shareholders   16,479 31,796 51.8%  
Pledged promoter(s) holding % 77.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ELDER PHARMA With:   FDC  UNICHEM LAB  PROCTER & GAMBLE HEALTH  AJANTA PHARMA  ALEMBIC  

Compare ELDER PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Over 300 Points Lower; Dow Futures Down by 31 Points(12:30 pm)

Share markets in India are presently trading on a negative note. The BSE Sensex is trading down by 390 points, down 0.8% at 48,644 levels.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (4QFY20); Net Profit Up 35.4% (Quarterly Result Update)

Jun 8, 2020 | Updated on Jun 8, 2020

For the quarter ended March 2020, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (up 35.4% YoY). Sales on the other hand came in at Rs 14 bn (up 9.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (3QFY20); Net Profit Down 4.9% (Quarterly Result Update)

Feb 6, 2020 | Updated on Feb 6, 2020

For the quarter ended December 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 4.9% YoY). Sales on the other hand came in at Rs 14 bn (up 3.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (2QFY20); Net Profit Down 10.3% (Quarterly Result Update)

Nov 11, 2019 | Updated on Nov 11, 2019

For the quarter ended September 2019, DIVIS LABORATORIES has posted a net profit of Rs 4 bn (down 10.3% YoY). Sales on the other hand came in at Rs 14 bn (up 12.5% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

DIVIS LABORATORIES 2018-19 Annual Report Analysis (Annual Result Update)

Oct 10, 2019 | Updated on Oct 10, 2019

Here's an analysis of the annual report of DIVIS LABORATORIES for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of DIVIS LABORATORIES. Also includes updates on the valuation of DIVIS LABORATORIES.

More Views on News

Most Popular

My Top Stock Recommendation for 2021 and Beyond(Profit Hunter)

Jan 5, 2021

My new guide will show you the huge potential in future proof businesses.

'Essential' Smallcap Stock Recommendations(Profit Hunter)

Jan 8, 2021

The smallcap rally has enough steam left in it. If you haven't joined yet, it is still not too late.

Is Nifty Forming a Top(Fast Profits Daily)

Jan 8, 2021

The charts are telling the bulls to be cautious.

Why Gold Hit Lower Circuit(Fast Profits Daily)

Jan 11, 2021

Were you shocked that bullion prices hit lower circuits on Friday on the MCX? Find out why it happened...

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

ELDER PHARMA SHARE PRICE


Sep 12, 2016 (Close)

TRACK ELDER PHARMA

  • Track your investment in ELDER PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

ELDER PHARMA 8-QTR ANALYSIS

COMPARE ELDER PHARMA WITH

MARKET STATS